Debiopharm begins Phase II trial of IAP inhibitor Debio 1143 to treat EOC

Swiss-based biopharmaceutical company Debiopharm has begun the clinical Phase II trial to evaluate the company’s inhibitor of apoptosis proteins (IAP) inhibitor, Debio 1143, to treat epithelial ovarian cancer (EOC).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news